Pernix Therapeutics (PTX) Guides Q4, FY11 EPS, Sales
Tweet
Share
E-mailGet Alerts PTX Hot Sheet
Join SI Premium – FREE
Pernix Therapeutics (AMEX: PTX) sees Q4 EPS of 13-15 cents, which compares to the Street estimate of 14 cents, on sales of $20-$22 million, vs. the consensus of $19.55 million.
Sees FY11 EPS of 33-35 cents, vs. the consensus of 34 cents, on sales of $59-$61 million, vs. the consensus of $58.77 million.
Sees FY11 EPS of 33-35 cents, vs. the consensus of 34 cents, on sales of $59-$61 million, vs. the consensus of $58.77 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Full Truck Alliance (YMM) Tops Q2 EPS by 10c; beats on guidance
Create E-mail Alert Related Categories
GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
